Macquarie Boosts Beigene (NASDAQ:ONC) Price Target to $313.00

Beigene (NASDAQ:ONC) had its price target raised by analysts at Macquarie from $259.00 to $313.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Macquarie’s price target indicates a potential upside of 15.16% from the company’s current price.

Beigene Trading Down 2.4 %

Shares of NASDAQ:ONC opened at $271.80 on Friday. The stock has a market cap of $26.60 billion, a price-to-earnings ratio of -32.99, a price-to-earnings-growth ratio of 7.73 and a beta of 0.63. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene has a twelve month low of $126.97 and a twelve month high of $287.88.

Beigene (NASDAQ:ONC) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.09 billion. As a group, sell-side analysts anticipate that Beigene will post -5.82 EPS for the current fiscal year.

Insider Activity at Beigene

In other Beigene news, Director Bros. Advisors Lp Baker sold 732,827 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $260.00, for a total value of $190,535,020.00. Following the sale, the director now directly owns 730,642 shares in the company, valued at $189,966,920. This represents a 50.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Xiaobin Wu sold 21,267 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $240.07, for a total transaction of $5,105,568.69. The disclosure for this sale can be found here. In the last three months, insiders have sold 790,950 shares of company stock worth $204,616,547. 7.43% of the stock is owned by company insiders.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.